Syndax Pharmaceuticals Quarterly Income Statements Chart
Quarterly
|
Annual
Syndax Pharmaceuticals Quarterly Income Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | 2020-06-30 | 2020-03-31 | 2019-12-31 | 2019-09-30 | 2019-06-30 | 2019-03-31 | 2018-12-31 | 2018-09-30 | 2018-06-30 | 2018-03-31 | 2017-12-31 | 2017-09-30 | 2017-06-30 | 2017-03-31 | 2016-12-31 | 2016-09-30 | 2016-06-30 | 2016-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| revenue: | ||||||||||||||||||||||||||||||||||||||
| product revenue | 28,600,000 | 20,042,000 | ||||||||||||||||||||||||||||||||||||
| collaboration revenue | 9,358,000 | |||||||||||||||||||||||||||||||||||||
| milestone and license revenue | 4,000,000 | 12,500,000 | 3,500,000 | |||||||||||||||||||||||||||||||||||
| total revenues | 37,958,000 | 20,042,000 | 4,000,000 | 12,500,000 | 3,500,000 | 126,576,000 | 12,375,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 1,193,000 | 305,000 | 305,000 | 305,000 | 305,000 | 305,000 | 305,000 | 305,000 | |||||||||
| yoy | 984.51% | 33297.36% | 3165.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -68.23% | 24.26% | 24.26% | 24.26% | 291.15% | 0.00% | 0.00% | 0.00% | |||||||||||||||||
| qoq | 89.39% | 401.05% | -68.00% | 257.14% | 922.84% | 3165.17% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -68.23% | 291.15% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |||||||||||
| operating expenses: | ||||||||||||||||||||||||||||||||||||||
| cost of product sales | 1,279,000 | 885,000 | ||||||||||||||||||||||||||||||||||||
| research and development | 62,227,000 | 61,636,000 | 65,529,000 | 70,971,000 | 48,655,000 | 56,492,000 | 55,126,000 | 39,087,000 | 34,764,000 | 34,054,000 | 31,841,000 | 26,901,000 | 29,734,000 | 30,022,000 | 23,900,000 | 25,606,000 | 16,871,000 | 21,870,000 | 15,522,000 | 14,408,000 | 10,943,000 | 9,562,000 | 9,502,000 | 9,923,000 | 12,290,000 | 11,279,000 | 15,820,000 | 14,095,000 | 14,851,000 | 15,339,000 | 16,598,000 | 12,188,000 | 9,862,000 | 9,552,000 | 8,474,000 | 12,274,000 | 6,131,000 | 4,786,000 |
| selling, general and administrative | 43,805,000 | 41,031,000 | 37,690,000 | 31,106,000 | 29,061,000 | 23,022,000 | ||||||||||||||||||||||||||||||||
| total operating expenses | 107,311,000 | 103,799,000 | 104,045,000 | 102,077,000 | 77,716,000 | 79,514,000 | 77,905,000 | 56,355,000 | 49,678,000 | 46,015,000 | 42,033,000 | 35,141,000 | 37,724,000 | 36,858,000 | 30,827,000 | 32,407,000 | 22,713,000 | 27,542,000 | 20,240,000 | 20,232,000 | 16,989,000 | 15,479,000 | 14,584,000 | 13,528,000 | 15,753,000 | 15,190,000 | 19,712,000 | 18,220,000 | 19,330,000 | 20,130,000 | 20,682,000 | 15,751,000 | 14,147,000 | 13,482,000 | 11,446,000 | 15,543,000 | 8,939,000 | 9,058,000 |
| income from operations | -69,353,000 | -83,757,000 | -96,365,000 | -89,577,000 | -74,216,000 | -79,514,000 | -77,905,000 | -56,355,000 | -49,678,000 | -46,015,000 | -42,033,000 | -35,141,000 | -37,724,000 | -36,858,000 | 95,749,000 | -20,032,000 | -22,334,000 | -27,163,000 | -19,861,000 | -19,853,000 | -16,610,000 | -15,100,000 | -14,205,000 | -13,149,000 | -15,374,000 | -14,811,000 | -19,333,000 | -17,841,000 | -18,951,000 | -19,751,000 | -19,489,000 | -15,446,000 | -13,842,000 | -13,177,000 | -11,141,000 | -15,238,000 | -8,634,000 | -8,753,000 |
| yoy | -6.55% | 5.34% | 23.70% | 58.95% | 49.39% | 72.80% | 85.34% | 60.37% | 31.69% | 24.84% | -143.90% | 75.42% | 68.91% | 35.69% | -582.10% | 0.90% | 34.46% | 79.89% | 39.82% | 50.98% | 8.04% | 1.95% | -26.52% | -26.30% | -18.87% | -25.01% | -0.80% | 15.51% | 36.91% | 49.89% | 74.93% | 1.37% | 60.32% | 50.54% | ||||
| qoq | -17.20% | -13.08% | 7.58% | 20.70% | -6.66% | 2.07% | 38.24% | 13.44% | 7.96% | 9.47% | 19.61% | -6.85% | 2.35% | -138.49% | -577.98% | -10.31% | -17.78% | 36.77% | 0.04% | 19.52% | 10.00% | 6.30% | 8.03% | -14.47% | 3.80% | -23.39% | 8.36% | -5.86% | -4.05% | 1.34% | 26.18% | 11.59% | 5.05% | 18.27% | -26.89% | 76.49% | -1.36% | |
| operating margin % | -182.71% | -417.91% | -2409.13% | -716.62% | -2120.46% | 75.65% | -161.87% | -5892.88% | -7167.02% | -5240.37% | -5238.26% | -4382.59% | -3984.17% | -3748.02% | -3469.39% | -4056.46% | -3907.92% | -5101.06% | -4707.39% | -5000.26% | -5211.35% | -1633.61% | -5064.26% | -4538.36% | -4320.33% | -3652.79% | -4996.07% | -2830.82% | -2869.84% | |||||||||
| other income, net: | ||||||||||||||||||||||||||||||||||||||
| royalty interest expense | -7,854,000 | -8,049,000 | ||||||||||||||||||||||||||||||||||||
| other interest expense | -4,000 | -2,000 | ||||||||||||||||||||||||||||||||||||
| interest income | 5,950,000 | 7,183,000 | 7,108,000 | 5,442,000 | 6,284,000 | 7,256,000 | 5,550,000 | 5,345,000 | 5,191,000 | 5,076,000 | 2,988,000 | 1,781,000 | 878,000 | 224,000 | 91,000 | 83,000 | 108,000 | 120,000 | 106,000 | 177,000 | 225,000 | 333,000 | 222,000 | 395,000 | 501,000 | 452,000 | 520,000 | 488,000 | 459,000 | 475,000 | 462,000 | 411,000 | 290,000 | 259,000 | 268,000 | 268,000 | 276,000 | 144,000 |
| other income | -586,000 | -221,000 | -106,000 | 32,000 | -86,000 | -87,000 | -55,000 | -66,000 | -93,000 | -147,000 | -52,500 | -295,000 | -31,000 | 116,000 | -37,250 | -41,000 | -50,000 | -57,000 | -33,000 | -126,000 | -39,000 | -20,000 | -17,000 | -75,000 | -43,000 | 57,000 | -24,000 | 15,000 | 104,000 | -122,000 | -76,000 | -53,000 | -87,000 | -53,000 | 58,000 | 1,000 | -18,000 | |
| total other income | -2,494,000 | -1,089,000 | 2,196,000 | 5,451,000 | 6,153,000 | 7,114,000 | 5,432,000 | 5,209,000 | 5,063,000 | 4,889,000 | 2,839,000 | -262,000 | 152,000 | -311,000 | 449,000 | -607,000 | -576,000 | -560,000 | -562,000 | -584,000 | -452,000 | -136,000 | 205,000 | 320,000 | 458,000 | 509,000 | 496,000 | 503,000 | 563,000 | 353,000 | 386,000 | 358,000 | 203,000 | 206,000 | 326,000 | 269,000 | 276,000 | -1,577,000 |
| net income | -71,847,000 | -84,846,000 | -94,169,000 | -84,126,000 | -68,063,000 | -72,400,000 | -72,473,000 | -51,146,000 | -44,615,000 | -41,126,000 | -39,194,000 | -35,403,000 | -37,572,000 | -37,169,000 | 96,198,000 | -20,639,000 | -22,910,000 | -27,723,000 | -20,423,000 | -20,437,000 | -17,062,000 | -15,236,000 | -14,000,000 | -12,829,000 | -14,916,000 | -14,302,000 | -18,837,000 | -17,338,000 | -18,388,000 | -19,398,000 | -19,103,000 | -15,088,000 | -13,639,000 | -12,971,000 | -10,815,000 | -14,969,000 | -8,358,000 | -10,330,000 |
| yoy | 5.56% | 17.19% | 29.94% | 64.48% | 52.56% | 76.04% | 84.91% | 44.47% | 18.75% | 10.65% | -140.74% | 71.53% | 64.00% | 34.07% | -571.03% | 0.99% | 34.27% | 81.96% | 45.88% | 59.30% | 14.39% | 6.53% | -25.68% | -26.01% | -18.88% | -26.27% | -1.39% | 14.91% | 34.82% | 49.55% | 76.63% | 0.79% | 63.18% | 25.57% | ||||
| qoq | -15.32% | -9.90% | 11.94% | 23.60% | -5.99% | -0.10% | 41.70% | 14.64% | 8.48% | 4.93% | 10.71% | -5.77% | 1.08% | -138.64% | -566.10% | -9.91% | -17.36% | 35.74% | -0.07% | 19.78% | 11.98% | 8.83% | 9.13% | -13.99% | 4.29% | -24.07% | 8.65% | -5.71% | -5.21% | 1.54% | 26.61% | 10.62% | 5.15% | 19.94% | -27.75% | 79.10% | -19.09% | |
| net income margin % | -189.28% | -423.34% | -2354.22% | -673.01% | -1944.66% | 76.00% | -166.78% | -6044.85% | -7314.78% | -5388.65% | -5392.35% | -4501.85% | -4020.05% | -3693.93% | -3384.96% | -3935.62% | -3773.61% | -4970.18% | -4574.67% | -4851.72% | -5118.21% | -1601.26% | -4946.89% | -4471.80% | -4252.79% | -3545.90% | -4907.87% | -2740.33% | -3386.89% | |||||||||
| net income attributable to common stockholders | -71,847,000 | -84,846,000 | -94,169,000 | -84,126,000 | -68,063,000 | -72,400,000 | -72,473,000 | -51,146,000 | -44,615,000 | -41,126,000 | -39,194,000 | -35,403,000 | -37,572,000 | -37,169,000 | 96,198,000 | -20,639,000 | -22,910,000 | -27,723,000 | -20,423,000 | -20,437,000 | -17,062,000 | -19,142,000 | -14,000,000 | -12,829,000 | -14,916,000 | -14,302,000 | -18,837,000 | -17,338,000 | -18,388,000 | -19,398,000 | -19,103,000 | -15,088,000 | -13,639,000 | -12,971,000 | -10,815,000 | -14,969,000 | -8,358,000 | -12,928,000 |
| net income per share | -0.658 | -0.98 | -0.8 | -0.85 | -0.493 | -0.73 | -0.64 | -0.59 | -0.46 | -0.58 | -0.62 | -0.63 | -0.345 | -0.4 | -0.44 | -0.54 | -0.44 | -0.46 | -0.42 | -0.56 | -0.44 | -0.41 | -0.47 | -0.53 | -0.71 | -0.68 | -0.74 | -0.79 | -0.82 | -0.68 | -0.7 | -0.71 | -0.52 | -0.84 | -0.47 | -2.85 | ||
| basic loss per share attributable to common stockholders | -0.83 | -0.98 | ||||||||||||||||||||||||||||||||||||
| diluted loss per share attributable to common stockholders | -0.83 | -0.98 | ||||||||||||||||||||||||||||||||||||
| weighted-average common shares used in calculating: | ||||||||||||||||||||||||||||||||||||||
| collaboration loss | 247,000 | |||||||||||||||||||||||||||||||||||||
| interest expense | -4,806,000 | -23,000 | -45,000 | -55,000 | -63,000 | -70,000 | -35,000 | -40,000 | -43,000 | -1,748,000 | -695,000 | -651,000 | 7,000 | -649,000 | -634,000 | -623,000 | -635,000 | -635,000 | -638,000 | -449,000 | ||||||||||||||||||
| other comprehensive loss: | ||||||||||||||||||||||||||||||||||||||
| unrealized gain on marketable securities | 92,750 | 1,188,000 | -61,000 | -974,000 | 87,750 | 119,000 | -238,000 | 470,000 | -412,500 | -270,000 | -695,000 | -685,000 | 3,750 | -6,000 | 8,000 | 13,000 | 13,250 | -64,000 | 69,000 | 48,000 | 12,500 | -33,000 | 50,000 | 33,000 | 27,000 | 54,000 | ||||||||||||
| comprehensive loss | -56,054,500 | -82,938,000 | -68,124,000 | -73,374,000 | -34,134,000 | -51,027,000 | -44,853,000 | -40,656,000 | -27,948,500 | -35,673,000 | -38,267,000 | -37,854,000 | -17,814,250 | -20,645,000 | -22,902,000 | -27,710,000 | -13,170,500 | -20,501,000 | -16,993,000 | -15,188,000 | -10,499,250 | -12,862,000 | -14,866,000 | -14,269,000 | -13,754,000 | -17,284,000 | -18,259,000 | -19,473,000 | -10,431,750 | -15,096,000 | -13,601,000 | -13,029,000 | -8,394,000 | -10,130,000 | ||||
| weighted-average number of common shares used to compute net income per share attributable to common stockholders —basic and diluted | 85,433,569 | 85,274,829 | 85,213,200 | 69,855,766 | 69,638,427 | 69,438,890 | 60,670,294 | 60,156,653 | 58,978,615 | 51,962,320 | 51,603,286 | 51,499,831 | 44,156,808 | 40,609,205 | 34,328,640 | 31,630,639 | 31,605,279 | 27,023,466 | 25,471,587 | 24,705,441 | ||||||||||||||||||
| general and administrative | 11,035,750 | 17,268,000 | 14,914,000 | 11,961,000 | 10,192,000 | 8,240,000 | 7,990,000 | 6,836,000 | 6,927,000 | 6,801,000 | 5,842,000 | 5,672,000 | 4,718,000 | 5,824,000 | 6,046,000 | 5,917,000 | 5,082,000 | 3,605,000 | 3,463,000 | 3,911,000 | 3,892,000 | 4,125,000 | 4,479,000 | 4,791,000 | 4,084,000 | 3,563,000 | 4,285,000 | 3,930,000 | 2,972,000 | 3,269,000 | 2,808,000 | 4,272,000 | ||||||
| license fees | 126,576,000 | 12,375,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 379,000 | 1,193,000 | 305,000 | 305,000 | 305,000 | 305,000 | 305,000 | 305,000 | 305,000 | ||||||||||||||
| other income: | ||||||||||||||||||||||||||||||||||||||
| other comprehensive income: | ||||||||||||||||||||||||||||||||||||||
| unrealized gains on marketable securities | 129,000 | -75,000 | -7,000 | -8,000 | 38,000 | -58,000 | -36,000 | 200,000 | ||||||||||||||||||||||||||||||
| weighted-average number of common shares used to compute net income per share attributable to common stockholders—basic and diluted | 24,478,269 | 22,239,996 | 19,497,581 | 18,231,602 | 17,899,481 | 17,769,514 | 4,541,536 | |||||||||||||||||||||||||||||||
| change in fair value of common stock warrant liability | -1,703,000 |
We provide you with 20 years income statements for Syndax Pharmaceuticals stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as earnings, sales and marketing expenses, research and development costs, profits, and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Syndax Pharmaceuticals stock. Explore the full financial landscape of Syndax Pharmaceuticals stock with our expertly curated income statements.
The information provided in this report about Syndax Pharmaceuticals stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.